European Joint Programme Cofund
The European Joint Programme Cofund (EJP) under Horizon 2020 is a new instrument designed to support coordinated national research and innovation programmes. EJPs are designed to pool together rather large national programmes, resources and capacities. They strive to not only bring together resources in terms of funding, but also in terms of capacity building, networking, demonstration and dissemination activities.
The European Consortium for the Development of Fusion Energy; EUROfusion manages and funds European fusion research activities on behalf of Euratom. The European fusion programme is based on the 'Roadmap to the realisation of fusion energy'. It aims at achieving all the necessary know-how to start the construction of a demonstration power plant (DEMO) by 2030, in order to reach the goal of fusion electricity in the grid by 2050. The EUROfusion European Joint Programme, started in 2014, has two major aims: 1) Preparing for ITER experiments (development of plasma regimes, investigate solutions to manage plasma heat exhaust, concepts for reducing heat loads in the ITER reactor) and 2) developing concepts for the fusion power demonstration plant DEMO. The Foundation for Fundamental Research on Matter (FOM-DIFFER) is the Dutch partner involved.
The CONCERT-European Joint Programme for the Integration of Radiation Protection Research functions as an umbrella for research initiatives jointly launched by the radiation protection research platforms MELODI, ALLIANCE, NERIS and EURADOS. It has started in 2015 and aims at jointly addressing common research needs in radiation protection and organize funding of research projects. The consortium also supports implementation of the revised European Basic Safety Standards by giving best possible advice based on evidence from research. Together with joint programming, CONCERT integrates activities such as access to research infrastructure, education and training and stakeholder involvement. CONCERT and EUROfusion are funded under Euratom. The Dutch partner involved is the National Institute for Public Health and the Environment (RIVM).
More information about the Strategic Research Agenda development can be found here.
The European Human Biomonitoring Initiative (HBM4EU) is a joint effort of twenty-six countries, the European Environment Agency and the European Commission. Its main aim is to coordinate and advance human biomonitoring in Europe. The project aims at optimising the use of human biomonitoring for risk assessments, health risk impacts and individualised treatments. The results will be used to evaluate existing policies and support new policy making. The HBM4EU consortium is a collaboration between scientists, chemical risk assessors and risk managers, including several Commission services, EU agencies and national representatives and started in 2017. The Dutch RIVM is involved as lead partner in this EJP. Other Dutch organisations involved as linked third parties are Utrecht University, VU University, RIKILT (part of) Wageningen Research, Radboud University Medical Center and the Netherlands Organisation for Applied Scientific Research (TNO).
View the brochure.
One Health EJP
There is currently one EJP funded under Societal Challenge 2: The One Health European Joint Programme. This EJP aims to create a sustainable European One Health framework through integration and alignment of medical, veterinary and food institutes. This is done by the joint programming of research agendas of the partners. The consortium consists of forty partner organisations from nineteen European countries. In each participating country at least one reference laboratory from the public health or human medicine domain, and one reference laboratory from the food / veterinary domain is involved. Dutch organisations participating in the One Health EJP are RIVM, Wageningen Bioveterinary Research WR and the Netherlands Centre for One Health (NCOH).
A provisional Strategic Research Agenda has been developed in 2016 during the preparatory phase of the One Health EJP.
Possibilities for two new EJP Cofunds, one on rare diseases and one on soil, are currently discussed with the European Commission.